Objective The purpose of this study was to understand the pathogenic mechanisms of enterococcal hemolysin and establish the foundation to diagnose and control relevant diseases.Methods Take 30 clean grade ICR mice were randomly divided into ten groups,each 6,1 to 4 groups according to 10-fold gradient amount per 1 ml intraperitoneal injection of 5× 107 cfu/ml~5×1010 cfu/ml of EF A7,group 5 as a control group injected 0.5 ml saline,take another 30 clean grade ICR mice,intraperitoneal injection of 5×107 cfu/ml~5×1010 cfu/ml of EF A7 cyl mutant by the same measures,compared to the original strains of mice infected with mutant strain LD50,and a week after infection mortality was observed in mice daily. Another seven groups of mice with the same bacterial concentration (5×109 cfu/ml)were injected intraperitoneally EF A7 and EF A7 cyl mutant,after infection 6 h,12 h and 24 h comparing the number of leukocytes in peripheral blood of mice,re-spectively,the concentration of TNF-αin the acute phase of cytokines.Results In the mouse peritonitis models the 50% le-thal dose (LD50)of EF A7 cyl mutant was 100 times lower than enterococcus faecalis EF A7.The differences of the survival percentage of EF A7 cyl mutant groups and EF A7 groups have significance (P<0.05).As the changes in boold leukocytes numbers and the TNF-αlevel.Conclusion Cyl gene is probably a major virulence factor of Enterococcus and plays an impor-tant role in the mouse peritonitis model.

Administration, Oral ; Chronic Disease ; Glucocorticoids ; administration & dosage ; therapeutic use ; Humans ; Sinusitis ; drug therapy

Based on the analysis on the most common type of scientific research and clinical application of stem cells, including embryonic stem cells , hematopoietic stem cells and mesenchymal stem cells as the breakthrough point, discusses common phenomenon and problems of ethics , scientific research and clinical study the moral life science century new topic, hope scientists, physicians, ethicists, caused by the administrative departments for pub-lic health thought , promote stem cells healthy and steady development .

Molecular target-based cancer therapy is playing a more and more important role in cancer therapy because of its high specificity, good tolerance and so on. There are different kinds of molecular targeted drugs such as monoclonal antibodies and small molecular kinase inhibitors, and more than 50 drugs have been approved since 1997. When the first monoclonal antibody, rituximab, was on the market. The development of molecular target-based cancer therapeutics has become the main approach. Based on this, we summarized the drugs approved by FDA and introduced their mechanism of actions and clinical applications. In order to incorporate most molecular targeted drugs and describe clearly various characteristics, we divided them into four categories: drugs related to EGFR, drugs related to antiangiogenesis, drugs related to specific antigen and other targeted drugs. The purpose of this review is to provide a current status of this field and discover the main problems in the molecular targeted therapy.

Molecular target-based cancer therapy is playing a more and more important role in cancer therapy because of its high specificity, good tolerance and so on. There are different kinds of molecular targeted drugs such as monoclonal antibodies and small molecular kinase inhibitors, and more than 50 drugs have been approved since 1997. When the first monoclonal antibody, rituximab, was on the market. The development of molecular target-based cancer therapeutics has become the main approach. Based on this, we summarized the drugs approved by FDA and introduced their mechanism of actions and clinical applications. In order to incorporate most molecular targeted drugs and describe clearly various characteristics, we divided them into four categories: drugs related to EGFR, drugs related to antiangiogenesis, drugs related to specific antigen and other targeted drugs. The purpose of this review is to provide a current status of this field and discover the main problems in the molecular targeted therapy.
Angiogenesis Inhibitors ; Antibodies, Monoclonal ; Drug Delivery Systems ; Humans ; Molecular Targeted Therapy ; Neoplasms ; drug therapy ; Protein Kinase Inhibitors ; Receptor, Epidermal Growth Factor ; antagonists & inhibitors

Data Mining ; Humans ; Medicine, Chinese Traditional ; Stomach Diseases ; therapy

Objective To investigate the effects of neuromuscular electrical stimulation (NMES) combined with swallowing training for relieving dysphagia in stroke patients.Methods A total of 150 chronic stroke patients at least 3 months post-stroke who were afflicted with dysphagia were randomly and evenly divided into a conventional swallowing training group,an NMES group,and an NMES combined with conventional swallowing training group.Prior to and after treatment,surface electromyography (sEMG) signals from the swallowing muscles were detected,swallowing function was evaluated using the standardized swallowing assessment (SSA),their swallowing was studied videofluoroscopically (VFSS),and a swallowing-related quality of life questionnaire (SWAL-QOL) was administered.Results There were significant differences in the maximum amplitude of sEMG signals,and the scores on the SSA,VFSS and SWAL-QOL in both groups between prior to and after treatment.After 4 weeks of treatment,the maximum amplitude of the sEMG signals and all three assessment scores were significantly higher where NMES had been combined with conventional swallowing training group compared with the other two groups.Indeed,there was no significant difference between the group which had received conventional swallowing training and the NMES groups.The analysis of coefficients revealed correlation between sEMG maximum amplitude and the SSA,VFSS and SWALQOL results.Conclusions NMES combined with conventional swallowing training is helpful for improving swallowing function in chronic stroke patients with dysphagia.

Purpose To explore the relationship between tumor suppressor in lung cancer 1 (TSLC1) protein expression and the carci-nogenesis and progression of human gastric carcinoma. Methods Expression of TSLC1 protein in 20 normal gastric mucosa, 30 intra-epithelial neoplasias ( IN) and 50 gastric cancers was examined by immunohistochemistry. Results The expression of TSLC1 in gas-tric cancer was 14. 00% which was lower than that in IN (46. 67%) and normal gastric mucosa (95. 00%, P<0. 05). TSLC1 ex-pression in high-grade IN was lower than that in low-grade IN and normal gastric mucosa (P<0. 05). TSLC1 expression in high-grade IN and gastric cancer was of no significant difference ( P>0. 05 ) . Expression of TSLC1 was significantly associated with lymph node metastasis and TNM in gastric cancer (P<0. 05). Conclusion The expression of TSLC1 is closely related to carcinogenesis, lymph node metastasis and clinical stage in gastric cancer, which suggest that TSLC1 may be a new target for the prevention and treatment of gastric cancer.

BACKGROUND:Fracture healing in diabetic patients is usual y unsatisfactory because of hormones and metabolic disorder, and an eventual multiple organ dysfunction resulting from high blood glucose. OBJECTIVE:To dynamical y observe the changes of cytokines during the fracture healing process in diabetic rats before and after insulin treatment. METHODS:A total of 120 Sprague-Dawley rats were included in this study. Of them, 90 rats intravenously injected with 5%tetraoxypyrimidine to induce rat models of diabetes were randomized into insulin treatment and diabetes groups, respectively. The remaining 30 rats were intravenously injected with equal volume of saline and selected as control group. The next day, blood glucose was determined. Healing at 1, 4, and 8 weeks after fracture were observed by the X-ray film. Biomechanical strength of the injured right tibia was measured at 4, 6, and 8 weeks after modeling. Cytokines in the osteotylus were determined by immunohistochemical staining and in situ hybridization technique. RESULTS AND CONCLUSION:The X-ray films showed that the speed of fracture healing in the diabetes group was slower than insulin treatment and control groups. Biomechanical strength of the osteotylus in the diabetes group was significantly decreased compared with the insulin treatment and control groups. However, there were no significant differences in above-mentioned parameters between the control and insulin treatment groups. Bone morphogenetic protein 2, basic fibroblast growth factor, transforming growth factor-beta, and vascular endothelial growth factor were widely expressed in the osteotylus and their expressions in diabetes group were significantly lower and slower than those in the control and insulin treatment groups. There was no statistical difference between control and insulin treatment groups. These results indicate that osteotylus formation speed, biomechanical strength, and growth factor expressions at the fracture site in diabetes rats were decreased compared with normal rats. Insulin treatment can enhance cytokine levels at the fracture site, thereby promoting the osteoblast proliferation and fracture healing.